<DOC>
	<DOC>NCT00133731</DOC>
	<brief_summary>The objective of this dose-ranging study is to determine the effects of several intravenous (IV) regimens of otamixaban on pharmacodynamic markers (including markers of thrombosis and coagulation markers), safety/tolerability, clinical efficacy and pharmacokinetics.</brief_summary>
	<brief_title>The SEPIA-PCI Trial: Otamixaban in Comparison to Heparin in Subjects Undergoing Non-Urgent Percutaneous Coronary Intervention</brief_title>
	<detailed_description />
	<mesh_term>Calcium heparin</mesh_term>
	<mesh_term>Otamixaban</mesh_term>
	<mesh_term>Heparin</mesh_term>
	<criteria>18 years of age or older Due to undergo nonurgent percutaneous coronary intervention (PCI) Planned treatment with aspirin and clopidogrel Recent acute coronary syndrome Patients at risk for, or with prior recent, bleeding Patients have received recent prior treatment with an anticoagulant Creatinine clearance &gt; 30 ml/min</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2008</verification_date>
</DOC>